The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study

被引:3
作者
Shehab, Abdulla [1 ]
Bhagavathula, Akshaya S. [1 ]
Elnour, Asim A. [2 ]
Al-Rasadi, Khalid [3 ]
Al-Shamsi, Saif [1 ]
机构
[1] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Internal Med, Al Ain, U Arab Emirates
[2] Gulf Med Univ, Pharm Coll, Dept Pharm Practice, Ajman, U Arab Emirates
[3] Sultan Qaboos Univ Hosp, Dept Biochem, Muscat, Oman
关键词
Statin; adverse drug reactions; drug safety; hyperlipidaemia; incidence; Middle East; COGNITIVE FUNCTION; BLOOD CHOLESTEROL; TASK-FORCE; ASSOCIATION; SAFETY; THERAPY; METAANALYSIS; GUIDELINES; SYMPTOMS; DISEASE;
D O I
10.2174/1570161117666190408164908
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: We investigated the incidence of adverse drug reactions (ADRs) in patients treated with statins for cardiovascular (CV) risk among the United Arab Emirates (UAE) population. Methods: This is a retrospective cohort study conducted among statin users attending 2 tertiary care centres: Al Ain and Tawam hospitals in Al Ain city, UAE. We retrieved the clinical profile of all the patients taking statins from January 2011 to January 2015 using our electronic database (Cerner (R)). Results: Among 556 patients (418 men; 138 women) taking statins, 237 ADRs were reported (186 men; 51 women). The incidence of ADRs was 40.7%, and was more frequent among patients at "high CV disease (CVD) risk" and "moderate CVD risk" than other risk categories. High CVD risk (odds ratio, 1.67; 95% confidence interval [CI], 1.19-2.34), vitamin D deficiency 1.45 (95% CI, 0.89-2.38), type 2 diabetes 1.22 (95% CI, 0.84-1.77) and hypertension 1.13 (95% CI, 0.70-1.83) are some of the factors that were associated with statin ADRs. Conclusion: The incidence of ADRs among statin users was 42.6%, and frequent ADRs (49%) were noted in patients with high CVD risk. Early identification of these ADRs should improve patient adherence to life-saving statin treatment.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 45 条
[1]   Statins, incident Alzheimer disease, change in cognitive function, and neuropathology [J].
Arvanitakis, Z. ;
Schneider, J. A. ;
Wilson, R. S. ;
Bienias, J. L. ;
Kelly, J. F. ;
Evans, D. A. ;
Bennett, D. A. .
NEUROLOGY, 2008, 70 (19) :1795-1802
[2]   Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].
Banach, Maciej ;
Rizzo, Manfredi ;
Toth, Peter P. ;
Farnier, Michel ;
Davidson, Michael H. ;
Al-Rasadi, Khalid ;
Aronow, Wilbert S. ;
Athyros, Vasilis ;
Djuric, Dragan M. ;
Ezhov, Marat V. ;
Greenfield, Robert S. ;
Hovingh, G. Kees ;
Kostner, Karam ;
Serban, Corina ;
Lighezan, Daniel ;
Fras, Zlatko ;
Moriarty, Patrick M. ;
Muntner, Paul ;
Goudev, Assen ;
Ceska, Richard ;
Nicholls, Stephen J. ;
Broncel, Marlena ;
Nikolic, Dragana ;
Pella, Daniel ;
Puri, Raman ;
Rysz, Jacek ;
Wong, Nathan D. ;
Bajnok, Laszlo ;
Jones, Steven R. ;
Ray, Kausik K. ;
Mikhailidis, Dimitri P. .
ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23
[3]   Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials [J].
Broncel, Marlena ;
Gorzelak-Pabis, Paulina ;
Sahebkar, Amirhossein ;
Serejko, Katarzyna ;
Ursoniu, Sorin ;
Rysz, Jacek ;
Serban, Maria Corina ;
Mozdzan, Monika ;
Banach, Maciej .
ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (05) :915-926
[4]   Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study [J].
Bruckert, E ;
Hayem, G ;
Dejager, S ;
Yau, C ;
Bégaud, B .
CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) :403-414
[5]   Long-Term Persistence with Statin Treatment in a Not-for-Profit Health Maintenance Organization: A Population-Based Retrospective Cohort Study in Israel [J].
Chodick, Gabriel ;
Shalev, Varda ;
Gerber, Yariv ;
Heymann, Anthony D. ;
Silber, Haim ;
Simah, Virginia ;
Kokia, Ehud .
CLINICAL THERAPEUTICS, 2008, 30 (11) :2167-2179
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]   Interpretation of the evidence for the efficacy and safety of statin therapy [J].
Collins, Rory ;
Reith, Christina ;
Emberson, Jonathan ;
Armitage, Jane ;
Baigent, Colin ;
Blackwell, Lisa ;
Blumenthal, Roger ;
Danesh, John ;
Smith, George Davey ;
DeMets, David ;
Evans, Stephen ;
Law, Malcolm ;
MacMahon, Stephen ;
Martin, Seth ;
Neal, Bruce ;
Poulter, Neil ;
Preiss, David ;
Ridker, Paul ;
Roberts, Ian ;
Rodgers, Anthony ;
Sandercock, Peter ;
Schulz, Kenneth ;
Sever, Peter ;
Simes, John ;
Smeeth, Liam ;
Wald, Nicholas ;
Yusuf, Salim ;
Peto, Richard .
LANCET, 2016, 388 (10059) :2532-2561
[8]   Statin use and risk of developing diabetes: results from the Diabetes Prevention Program [J].
Crandall, Jill P. ;
Mather, Kieren ;
Rajpathak, Swapnil N. ;
Goldberg, Ronald B. ;
Watson, Karol ;
Foo, Sandra ;
Ratner, Robert ;
Barrett-Connor, Elizabeth ;
Temprosa, Marinella .
BMJ OPEN DIABETES RESEARCH & CARE, 2017, 5 (01)
[9]   The role of lipid-lowering drugs in cognitive function: A meta-analysis of observational studies [J].
Etminan, M ;
Gill, S ;
Samii, A .
PHARMACOTHERAPY, 2003, 23 (06) :726-730
[10]   Statin-Associated Adverse Cognitive Effects: Survey Results from 171 Patients [J].
Evans, Marcella A. ;
Golomb, Beatrice A. .
PHARMACOTHERAPY, 2009, 29 (07) :800-811